Business Description
Sartorius Stedim Biotech SA
NAICS : 334510
SIC : 3844
ISIN : FR0013154002
Share Class Description:
LTS:0RG8: Ordinary SharesCompare
Compare
Traded in other countries / regions
DIM.France0RG8.UKSDMHF.USA56S1.GermanyDIM.AustriaDIM.Mexico IPO Date
2007-12-18Description
Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.18 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.73 | |||||
| Debt-to-EBITDA | 6.64 | |||||
| Interest Coverage | 2.25 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 3.52 | |||||
| Beneish M-Score | -2.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 13.3 | |||||
| 3-Year EBITDA Growth Rate | 9.9 | |||||
| 3-Year EPS without NRI Growth Rate | -9.9 | |||||
| 3-Year FCF Growth Rate | 1.9 | |||||
| 3-Year Book Growth Rate | 22.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 24.19 | |||||
| Future 3-5Y Total Revenue Growth Rate | 6.77 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.92 | |||||
| 9-Day RSI | 53.95 | |||||
| 14-Day RSI | 50.68 | |||||
| 6-1 Month Momentum % | 2.72 | |||||
| 12-1 Month Momentum % | -9.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.14 | |||||
| Quick Ratio | 1.15 | |||||
| Cash Ratio | 0.66 | |||||
| Days Inventory | 261.62 | |||||
| Days Sales Outstanding | 51.84 | |||||
| Days Payable | 81.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.38 | |||||
| 3-Year Dividend Growth Rate | 61.8 | |||||
| Forward Dividend Yield % | 0.38 | |||||
| 5-Year Yield-on-Cost % | 1.33 | |||||
| Shareholder Yield % | -7.11 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 42.38 | |||||
| Operating Margin % | 14.03 | |||||
| Net Margin % | 5.04 | |||||
| FCF Margin % | 20.37 | |||||
| ROE % | 3.2 | |||||
| ROA % | 1.31 | |||||
| ROIC % | 2.93 | |||||
| ROC (Joel Greenblatt) % | 12.87 | |||||
| ROCE % | 3.89 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 174 | |||||
| Forward PE Ratio | 40.95 | |||||
| PE Ratio without NRI | 174 | |||||
| Shiller PE Ratio | 46.5 | |||||
| Price-to-Owner-Earnings | 73.75 | |||||
| PEG Ratio | 6.93 | |||||
| PS Ratio | 8.79 | |||||
| PB Ratio | 4.78 | |||||
| Price-to-Free-Cash-Flow | 42.94 | |||||
| Price-to-Operating-Cash-Flow | 30.42 | |||||
| EV-to-EBIT | 72.06 | |||||
| EV-to-Forward-EBIT | 32.06 | |||||
| EV-to-EBITDA | 46.65 | |||||
| EV-to-Forward-EBITDA | 25.55 | |||||
| EV-to-Revenue | 9.6 | |||||
| EV-to-Forward-Revenue | 6.47 | |||||
| EV-to-FCF | 45.07 | |||||
| Price-to-Projected-FCF | 2.65 | |||||
| Price-to-DCF (Earnings Based) | 4.33 | |||||
| Price-to-DCF (FCF Based) | 1.1 | |||||
| Price-to-Median-PS-Value | 0.71 | |||||
| Price-to-Peter-Lynch-Fair-Value | 11.45 | |||||
| Earnings Yield (Greenblatt) % | 1.4 | |||||
| FCF Yield % | 2.41 | |||||
| Forward Rate of Return (Yacktman) % | 16.02 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sartorius Stedim Biotech SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2,068.6 | ||
| EPS (TTM) (€) | 1.1 | ||
| Beta | 1.33 | ||
| Volatility % | 49.32 | ||
| 14-Day RSI | 50.68 | ||
| 14-Day ATR (€) | 5.970359 | ||
| 20-Day SMA (€) | 179.2075 | ||
| 12-1 Month Momentum % | -9.21 | ||
| 52-Week Range (€) | 139.45 - 280.8 | ||
| Shares Outstanding (Mil) | 97.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sartorius Stedim Biotech SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sartorius Stedim Biotech SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sartorius Stedim Biotech SA Frequently Asked Questions
What is Sartorius Stedim Biotech SA(LTS:0RG8)'s stock price today?
The current price of LTS:0RG8 is €181.13. The 52 week high of LTS:0RG8 is €280.80 and 52 week low is €139.45.
When is next earnings date of Sartorius Stedim Biotech SA(LTS:0RG8)?
The next earnings date of Sartorius Stedim Biotech SA(LTS:0RG8) is 2025-01-17 Est..
Does Sartorius Stedim Biotech SA(LTS:0RG8) pay dividends? If so, how much?
The Dividend Yield %  of Sartorius Stedim Biotech SA(LTS:0RG8) is 0.38% (As of Today), Highest Dividend Payout Ratio of Sartorius Stedim Biotech SA(LTS:0RG8) was 0.51. The lowest was 0.09. And the median was 0.2. The  Forward Dividend Yield % of Sartorius Stedim Biotech SA(LTS:0RG8) is 0.38%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers